In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

AbbVie recently signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

The healthcare industry is a behemoth, with annual expenditures totaling $4.9 trillion in the United States alone. It's a ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...